Literature DB >> 27572300

Overview and guidelines of off-label use of methotrexate in ectopic pregnancy: report by CNGOF.

Henri Marret1, Arnaud Fauconnier2, Gil Dubernard3, Hélène Misme3, Laurence Lagarce4, Magali Lesavre5, Hervé Fernandez5, Camille Mimoun2, Claire Tourette6, Sandra Curinier7, Benoit Rabishong7, Aubert Agostini6.   

Abstract

Our objective is to describe off-label use of methotrexate in ectopic pregnancy treatment using evidence based medicine. The patient group includes all women with a pregnancy outside the usual endometrium, or of unknown location. Method used was a Medline search on ectopic pregnancy managed using methotrexate treatment; evidence synthesis was done based on this current literature analysis. Level of evidence (LE) were given according to the centre for evidence base medicine rules. Grade was proposed for guidelines but no recommendation was possible as misoprostol is off label use for all the indications studied. In the absence of any contraindication, the protocol recommended for medical treatment of ectopic pregnancy is a single intramuscular injection of methotrexate (MTX) at a dosage of 1mg/kg or 50mg/m(2) (Grade A). It can be repeated once at the same dose should the hCG concentration not fall sufficiently. Pretreatment laboratory results must include a complete blood count and kidney and liver function tests (in accordance with its marketing authorization). MTX is an alternative to conservative treatment such as laparoscopic salpingotomy for uncomplicated tubal pregnancy (Grade A) with pretreatment hCG levels≤5000IU/l (Grade B). Expectant management is preferred for hCG levels<1000IU/l or in the process of spontaneous decreasing (Grade B). Intramuscular MTX is also recommended after the failure of surgical salpingotomy (Grade C) or immediately after surgery, if monitoring is not possible. Except in special circumstances, a local insitu ultrasound-guided MTX injection is not recommended for unruptured tubal pregnancies (Grade B). In situ MTX is an option for treating cervical, interstitial, or cesarean-scar pregnancies (Grade C). In pregnancies of unknown location persisting more than 10days in an asymptomatic woman who has an hCG level>2000IU/l, routine MTX treatment is an option. MTX is not indicated for combination with treatments such as mifepristone or potassium.
Copyright © 2016. Published by Elsevier Ireland Ltd.

Entities:  

Keywords:  Cervical pregnancy; Ectopic pregnancy; Guideline; Interstitial pregnancy; Methotrexate; hCG

Mesh:

Substances:

Year:  2016        PMID: 27572300     DOI: 10.1016/j.ejogrb.2016.07.489

Source DB:  PubMed          Journal:  Eur J Obstet Gynecol Reprod Biol        ISSN: 0301-2115            Impact factor:   2.435


  8 in total

1.  Medication-Wide Association Study Using Electronic Health Record Data of Prescription Medication Exposure and Multifetal Pregnancies: Retrospective Study.

Authors:  Lena Davidson; Silvia P Canelón; Mary Regina Boland
Journal:  JMIR Med Inform       Date:  2022-06-07

2.  Use of methotrexate in the treatment of ectopic pregnancies: a retrospective single center study.

Authors:  C Beguin; G Brichant; L De Landsheere; L Tebache; S Karampelas; L Seidel; M Nisolle
Journal:  Facts Views Vis Obgyn       Date:  2020-03-27

3.  Early Ectopic Pregnancy Refractory to Methotrexate Treatment: A Case Report.

Authors:  ChiaJu Lin; HsiaoYun Hsieh
Journal:  Cureus       Date:  2021-11-18

4.  Dispensing of Potentially Harmful Prescription Drugs in 1.8 Million Pregnant Women in France: A Nationwide Study Based on Two Risk Classification Systems.

Authors:  Pierre-Olivier Blotière; Christine Damase-Michel; Alain Weill; Géric Maura
Journal:  Drug Saf       Date:  2021-10-06       Impact factor: 5.606

5.  Multidosing Intramuscular Administration of Methotrexate in Interstitial Pregnancy With Very High Levels of β-hCG: A Case Report and Review of the Literature.

Authors:  Valeria Conti; Giovanni Luciano; Giovanni Pecoraro; Roberto Iovieno; Amelia Filippelli; Maurizio Guida
Journal:  Front Endocrinol (Lausanne)       Date:  2018-07-10       Impact factor: 5.555

6.  The role of ultrasonography in methotrexate therapy for ectopic pregnancy.

Authors:  Piotr Czuczwar
Journal:  J Ultrason       Date:  2018

7.  Luteal blood flow as a predictive factor for methotrexate treatment outcomes in women with unruptured tubal pregnancy.

Authors:  Li Wang; Meili Pei; Ting Yang; Juan Zhao; Xiaofeng Yang
Journal:  BMC Pregnancy Childbirth       Date:  2020-03-30       Impact factor: 3.007

8.  Predictors and clinical features of methotrexate (MTX) therapy for ectopic pregnancy.

Authors:  Jing Zhang; Yu Zhang; Lu Gan; Xiao-Ying Liu; Shan-Ping Du
Journal:  BMC Pregnancy Childbirth       Date:  2020-10-29       Impact factor: 3.007

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.